Program Overview | Technology Platform | Research Strategies |
Products Under Development
Atherosclerosis is an area of large unmet medical need. This disease is the leading cause of morbidity and mortality globally and claims more lives each year than all forms of cancer combined. Coronary Artery Disease (CAD) is the most common and serious consequence of this disease. According to the American Heart Association 61.8 million Americans have some form of cardiovascular disease. The current treatment strategies are only partially effective and there is an urgent need for additional therapies.
At Discovery Research, we are committed to driving improvements by developing breakthrough treatments that target the key pathways causing cardiovascular diseases. We have three main areas of focus in this segment:
- Atheroscelrosis
- Restenosis
- Dyslipidemia
Our approach is based on our understanding of the signaling events between components of the sub-endothelial matrix and our expertise in relevant areas of cardiovascular biology.( Also read about our technology platform CMS Pathway™). The plaque build up contains three steps - inflammation of blood vessel, cell proliferation and thrombosis at plaque site. We have developed a breakthrough treatment strategy and are currently developing compounds that effectively block all three processes involved in plaque build up. Our target is the protein - Perlecan that can block inflammation, thrombosis and proliferation.
Researchers at Discovery Research are researching to obtain a detailed understanding of the proprietary Cell Matrix System Pathway (CMS Pathway™) and its role in human disease. Endothelial cells and smooth muscle cells in a blood vessel wall communicate through molecules in the sub-endothelial matrix. The sub-endothelial matrix is a complex organization of protein and carbohydrate molecules, secreted by both the endothelial and smooth muscle cells. These molecules include the basis of signaling between the two cell types and the rest of the body.
Currently, we are focusing on research programs to develop small molecule therapeutics that are designed to intervene in the CMS Pathway™ and modulate the alterations in signaling a positive clinical effect in Atherosclerosis and Restenosis. Additional Indications that are being targeted by this research are Acute and Chronic Inflammatory Disease.
Atherosclerosis:
Our drug candidates under this area are RUS 3108.
|
